Plus500 does not provide CFD services to residents of the United States. Visit our U.S. website at us.plus500.com.

Markets React to UK Vaccine Approval

FTSE100 (UK100) futures jumped 1.1% yesterday and Pfizer (PFE) climbed as high as 2.3%  to $41.32 during yesterday’s trading following COVID-19 vaccine approval before closing at $40.72.

UK vaccine

Yesterday, the UK’s health agency, the MHRA, announced approval of Pfizer and BioNtech’s request for emergency approval for their COVID-19 vaccine. This makes the UK the first country to have approved any Coronavirus vaccine, which will begin being administered as early as next week.

Currently, there are 800,000 doses on the way to the UK with elderly people and their caretakers slated to be the first to receive this vaccine. This comes on the heels of governments across Europe and some American localities imposing new lockdown restrictions to help curb the spread of the virus. In reaction to this long anticipated COVID vaccine, some shares, commodities, and index futures moved higher during yesterday’s trading.

Vaccine developers saw a boost in share prices, such as Moderna (MRNA), which closed 1.4% higher. Even Astrazeneca (AZN-L), who need to retest their vaccines after inconsistent testing reports, notched 1.2% higher to £7972 per share before closing at £7,926.

Oil Climbs Following Vaccine Approval

Oil futures traded higher yesterday as markets looked beyond the pandemic to an eventual softening of lockdowns, following the vaccine news. Since March of this year, Oil has struggled to return to pre-pandemic valuations. 

American West Texas Intermediate Oil (CL) futures rose 3.5% to a high of $45.88 during yesterday’s trading before closing the day at $44.94. North Sea Brent Crude (EB) futures rose 3.7% to a high of $48.74 during yesterday’s trading, yet closed the day at $47.98. This also pushed British Oil and gas producer, BP (BP-L) to close 4.7% higher during yesterday’s trading.

This vaccine approval indicates a turning point in the fight against the Coronavirus. While it may be some time before full populations can be immunized, leaving traders to speculate on the potential for future market volatility.

Articulos mas recientes


Obtén más con Plus500

Amplíe sus conocimientos

Aprende a través de vídeos informativos, seminarios web, artículos y guías con nuestra completa Academia de trading.

Explora nuestros +Insights

Descubre las tendencias dentro y fuera de Plus500.


Esta información fue redactada por Plus500 Ltd. La información se proporciona solo con fines generales y no tiene en cuenta ninguna circunstancia u objetivo personal. Antes de actuar con base en este material, debe considerar si es adecuado para sus circunstancias particulares y, si es necesario, buscar asesoramiento profesional. No se ofrece representación ni garantía en cuanto a la exactitud o integridad de esta información. No constituye asesoramiento financiero, de inversión ni de otro tipo en el que pueda confiar. Cualquier referencia a desempeños pasados, rendimientos históricos, proyecciones futuras y pronósticos estadísticos no son garantía de rendimientos futuros o desempeños futuros. Plus500 no será responsable del uso que pueda hacerse de esta información y de las consecuencias que puedan resultar de dicho uso. Por lo tanto, cualquier persona que actúe basándose en esta información lo hará a su propia discreción. La información no ha sido preparada según los requisitos legales creados para promover la independencia de la investigación sobre inversiones.

Los CFD de criptomonedas no están disponibles para clientes minoristas.

Empezar a negociar